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ABSTRACT
Background:  Hepatocellular  carcinoma  (HCC)  is  one  of  the  most  common  malignancies 
worldwide. Annually, about 200,000 patients died of HCC in China. Liver transplantation 
(LT) holds great theoretical appeal in treating HCC. However, the high recurrence rate after 
transplantation is the most important limiting factor for long-term survival.
Objectives: To assess the value of alpha-fetoprotein (AFP) messenger RNA (mRNA), Glypican-3 
(GPC3) mRNA-expressing cells in the peripheral blood (PB) for prediction of HCC recurrence 
following orthotopic liver transplantation (OLT).
Patients and Methods: 29 patients with HCC who underwent OLT with a minimum clinical 
follow-up of 12 months were included in this retrospective study. We detected AFP mRNA, 
GPC3 mRNA-expressing cells in the PB by TaqMan real-time reverse transcriptase-polymerase 
chain reaction (RT-PCR), pre-, intra- and post-operatively. The early recurrence of patients was 
evaluated.
Results: 8 (28%), 15 (52%), and 9 (31%) patients had AFP mRNA detected pre-, intra-, and post-
operatively, respectively. With 12 months of follow-up, HCC recurred in 7 (24%) patients. Uni-
variate analysis revealed that positive pre- and post-operative AFP mRNA, TNM stage as well 
as vascular invasion were significant predictors for the HCC recurrence. Multivariate analysis 
revealed that being positive for AFP mRNA pre-operatively remained a significant risk fac-
tor for HCC recurrence after OLT. GPC3 mRNA was expressed in all PB samples. There was no 
significant difference in the expression levels of GPC3 mRNA between the HCC and control 
groups. There were no significant differences in GPC3 mRNA expression values between 
those patients with and without tumor recurrence.
Conclusions: The pre-operative detection of circulating AFP mRNA-expressing cells could be a 
useful predictor for HCC recurrence following OLT. GPC3 mRNA-expressing cells in PB seem 
to have no diagnostic value.
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Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies worldwide, with a global incidence of 
500,000 new cases per year; 82% of cases (and deaths) occur 
in developing countries (with 55% in China) (1, 2). HCC is up to 
four times more common in men than in women; 60%–90% of 
these tumors develop in a cirrhotic liver (3). Each year, about 
200,000 patients died of HCC in China. Liver transplanta-
tion (LT), which offers the potential to both resect the entire 
potentially tumor-bearing liver and eliminate the cirrhotic 
tissues, holds great theoretical appeal in treating HCC. How-
ever, recurrence of HCC is a significant cause of mortality af-
ter LT (4, 5). Even with the implementation of Milan criteria, 
recurrence rates have been shown to be 8%–15% in most stud-
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ies (6-8). The high recurrence rate after transplantation is the 
most important limiting factor for long-term survival. Estab-
lishment of a direct and accurate method to predict tumor 
recurrence and/or micrometastasis after LT is needed. The 
human α-fetoprotein (AFP) messenger RNA (mRNA) is gen-
erally accepted as a tumor-specific marker. There are some 
reports to identify AFP mRNA for detecting isolated tumor 
cells (ITC) in peripheral blood (PB) (9, 10). It sounds theoreti-
cally reasonable to consider the detection of circulating HCC 
cells as being predictive for HCC recurrence after LT. We have 
established an accurate and sensitive method for the detec-
tion of circulating HCC cells by RT-PCR method to quantify 
AFP mRNA (11). Glypican-3 (GPC3) is a member of the glypican 
family of cell-surface heparin-sulfate proteoglycans, which 
is linked to the cell surface through a glycosylphosphati-
dylinositol (GPI) anchor (12). There has been considerable 
interest in GPC3, because it is markedly overexpressed in a 
high proportion of HCCs and promotes the growth of HCCs 
(13-15). Some clinical research studies reported GPC3 over-
expression in HCC both at mRNA and protein levels (16, 17). 
Based on these results, it has been proposed that GPC3 could 
be used as a serum and histochemical marker for HCC. De-
spite this clinical interest in GPC3, it is still unclear whether 
GPC3 mRNA detectable in PB is related to HCC diagnosis and 
predicts its recurrence.
Objectives
 In the present study, we applied TaqMan real-time RT-PCR 
to assess the usefulness of detecting AFP mRNA and GPC3 
mRNA-expressing cells in the PB for predicting the risk of 
HCC recurrence after orthotopic liver transplantation (OLT).
Patients and Methods
Patients and Sample Collection
Twenty-nine liver transplant recipients with HCC (27 men, 2 
women; mean age: 48 years, age range: 37–62 years) who un-
derwent OLT in Orient Organ Transplant Center during 2008 
were included in this retrospective study. The diagnosis of 
HCC  was  confirmed  by  pathologic  study  by  experienced 
pathologists. The criteria for OLT in patients with HCC are 
absence of extrahepatic malignancies, macroscopic tumor 
thrombosis, or extrahepatic metastasis of HCC. Of the 29 
studied patients, 27 had hepatitis B virus (HBV)-induced cir-
rhosis, and two patients had hepatitis C virus (HCV)-induced 
cirrhosis. Twelve patients had received treatment for HCC; 
treatments included resection, radiotherapy or transcath-
eter  hepatic  arterial  chemoembolization  (TACE)  prior  to 
transplantation. The remaining 17 patients had not received 
any treatments. Clinical characteristics of HCC patients are 
summarized in Table 1. All recipients had undergone success-
ful OLT (livers were from cadaveric donors who voluntarily 
donated). No organs were obtained from executed prisoners. 
Post-operatively, all the patients received standard post-liver 
transplantation care in the intensive care unit. They received 
the same immunosuppressive therapy with tacrolimus, da-
clizumab,  mycophenolate  mofetil,  and  methylpredniso-
lone. Short-term tumor recurrences (any recurrence during 
the first year) of HCC were assessed by measurements of AFP 
and computed tomography (CT)/magnetic resonance imag-
ing of the chest and abdomen according to a well-defined 
protocol (ie, every 3 months). As the control group, we also 
randomly selected 20 patients (15 men, 5 women; mean age: 
46 years, age range: 30–65 years) without HCC who under-
went OLT due to chronic HBV or HCV cirrhosis as control 
group during the same period and 20 healthy volunteers (15 
men, 5 women; mean age: 43 years, age range: 27–60 years) 
who had no sign of hepatitis or liver functional abnormality. 
There were no statistically significant differences in age and 
sex between the study groups. 
The present study was approved by the Institutional Ethics 
Committee of our institute. The informed consent was ob-
tained from each patient. The procedure met all applicable 
institutional guidelines of our institute, and governmental 
regulations concerning the ethical use of donated organs. 
PB (15 mL) was drawn with a sterile syringe containing eth-
ylenediaminetetraacetic acid (EDTA). PB samples were ob-
tained  at  the  following  time  points:  pre-operatively  (just 
before the skin incision), intra-operatively (during the anhe-
patic period), and post-operatively (the first week, the first 
month, and the second month after the operation) from all 
29 patients. AFP mRNA detectable each time after operation 
was considered as “real post-operative AFP mRNA positivity.” 
In the meantime, the control group who provided informed 
consent were also tested for AFP mRNA, and GPC3 mRNA.
RNA extraction and real-time RT-PCR
Total RNA was extracted with PB mononuclear cells (PBMCs) 
with TRIzol reagent (GIBCO-BRL, USA). The real-time RT-PCR 
used for the detection of AFP mRNA was performed as de-
scribed previously (11). The sequences of primers and TaqMan 
probe of GPC3 were: forward primer (5’-AGAGGCCTTTGAAAT-
TGT-3’), reverse primer (5’-AAATACTTTCAGGTCACGTC-3’), and 
probe (5’-FAM-ATGCCAAGAACTACA CCAATGC-TAMRA-3’). The 
conditions for every PCR reaction were 15 min at 95 °C, fol-
lowed by 40 cycles of denaturation for 20 seconds at 95 °C 
and annealing/extension for 60 seconds at 60 °C. Data were 
analyzed with Sequence Detection Software. The level of ex-
pression was calculated using the formula (18):
 
The RT-PCR assay was repeated twice and performed with 
an ABI Prism GeneAmp 7300 Sequence Detection System (Ap-
plied Biosystems, Foster City, CA).
Statistical analysis
Kaplan-Meier survival analysis and log-rank test were used 
to derive the survival curve. To assess the risk factors, univar-
iate and multivariate analyses were performed using the Ka-
plan-Meier method (long-rank test) and Cox’s proportional 
hazards model. Comparison between two groups was made 
by independent Student’s t test for numerical variables, and 
x
2 test for categorical variables. One-way ANOVA with Bonfer-
roni post hoc test was used for comparisons between more 
than two groups. A p value <0.05 was considered statistically 
significant. Analyses were made using SPSS® software ver 12 
for Windows® (SPSS, Chicago, IL, USA).
Results
All patients had at least one year of follow-up. HCC recurred 
Relative expression =
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currence in liver transplant patients (22). Whereas Cheung, 
et al, showed that plasma AFP mRNA level revealed insig-
nificant association with the HCC recurrence after LT (23). A 
higher risk of HCC recurrence in patients with pre-operative 
AFP mRNA or in patients with AFP mRNA persistently posi-
tive pre-operatively has been reported in the literature (23, 
24). This study showed that the positive expression rate of 
AFP mRNA was 28% (8/29) in PB samples pre-operatively. Sev-
eral literature reports showed that the positive rate of pre-
operative AFP mRNA was 20%–50% in hepatic resection and 
transplantation (24-27). This variability can be attributed to 
in vitro instability of mRNA, differences concerning labora-
tory techniques, primer selection, time between sample col-
lection and processing, and different patient populations. 
Pre-operative presence of AFP mRNA in PB may represent 
shedding of cells from primary HCC; another possibility is 
the presence of unfound occult micrometastasis that was 
undetectable pre-operatively.
Operative manipulation would enhance the dissemination 
of HCC cells into PB; this cell spread could be partly respon-
sible for tumor recurrence after OLT, although this is an in-
termittent and transient phenomenon. However, it has been 
shown that surgical intervention induces a release of non-
neoplastic liver cells into the circulation and increases false-
positive signals of AFP mRNA. To reduce the likelihood of 
false-positive results, the post-operative blood samples were 
taken one week after transplantation, as liberated non-neo-
plastic cells are presumably filtered from the PB within one 
week, as previously proposed by Ijichi, et al (24). Our study 
showed that consistent positive results of AFP mRNA (three 
times test after operation) should be considered a real post-
operative positive result. One possible explanation for post-
operative positive result is that a proportion of cancerous 
in 7 (24%) of 29 patients at 4–11 (median 6.8) months after 
OLT during the follow-up period. AFP mRNA was positive in 
8 (28%) patients pre-operatively, in 15 (52%) intra-operatively, 
and in 9 (31%) post-operatively. AFP mRNA was positive pre-
operatively in 6 (21%) patients—pre-, intra- and post-opera-
tively. None of healthy volunteers had AFP mRNA-expressing 
cells in their PB, and one (5%) of patients with chronic HBV or 
HCV cirrhosis without HCC, had AFP mRNA-expressing cells 
in his PB pre-operatively; these frequencies were significant-
ly different from pre-operative patients with HCC (p = 0.013, 
p = 0.030, respectively). Of the nine variables assessed, four 
were significantly related to recurrence in univariate analy-
sis. These were TNM stages, vascular invasion, pre-operative 
AFP mRNA, and post-operative AFP mRNA (Table 2). The pres-
ence of pre-operative AFP mRNA-positive cells in PB was in fa-
vor of a lower recurrence-free survival rate (Figure 1). Pre-op-
erative detection of AFP mRNA was found as an independent 
risk factor for HCC recurrence by multivariate analysis using 
Cox’s proportional hazards model (Table 3). GPC3 mRNA was 
expressed in all PB samples. There was no significant differ-
ence in expression levels of GPC3 mRNA between the HCC 
group (7.9 ± 3.4×10-3) and healthy volunteers (6.1 ± 2.8×10-3) 
(p = 0.056), and between patients with chronic viral hepati-
tis and cirrhosis (6.7 ± 2.9×10-3) (p = 0.214). Of those patients 
with (6.0 ± 2.5×10-3) and without (6.2 ± 2.6×10-3) tumor re-
currence after OLT, there was also no significant difference 
in GPC3 mRNA expression values (p = 0.858).
Discussion
It is a well-developed and mature technique in recent years 
that marked RNA of tumor cells in PB was amplified using 
RT-PCR to confirm the presence of tumor cells in blood (9, 
10). Previous studies showed that AFP mRNA may be inves-
tigated as a surrogate marker for isolated tumor cells (ITC) 
of HCC, and may predict HCC recurrence after curative he-
patectomy (19, 20). However, the specificity and prognostic 
value of AFP mRNA for circulating HCC tumor cells remains 
questionable (21). Furthermore, the clinical significance of 
this molecular technique remains controversial in patients 
for prediction of HCC recurrence after LT. A recent study by 
Marubashi, et al, showed that the detection of AFP mRNA in 
PB pre-operatively could be associated with the HCC recur-
rence and might serve as a useful predictor for the HCC re-
Figure 1. Recurrence-free survival of those with negative pre-operative AFP 
mRNA was higher than those with positive pre-operative AFP mRNA (Kaplan-
Meier method)
Clinical features
Gender (male/female) 27/2
Age (year)
[Mean (rang)]
48 (37–62) 
Child-Pugh score [No (%)]
A
B + C
14 (48%)
15 (52%)
TNM stage [No (%)]
I - II
III - IVa
12 (41%)
17 (59%)
Milan criteria [No (%)]
Within
Beyond
14 (48%)
15 (52%)
Tumor size [No (%)]
< 5 cm
≥ 5 cm
16 (55%)
13 (45%)
Tumor number [No (%)]
< 3
≥ 3
18 (62%)
11 (38%)
Vascular invasion [No (%)]
Positive
Negative
15 (52%)
14 (48%)
Pre-operative locoregional treatment [No (%)]
No
Yes
17 (59%)
12 (41%)
Serum AFP [No (%)]
≤ 20 μg/L
> 20 μg/L
10 (34%)
19 (66%)
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cells released from the surgical procedure would still stay 
in the PB for more than one week in an immunosuppressed 
patient. Another possibility would be the presence of unre-
sected occult metastases that left undetectable at the time 
of surgery. The overall recurrence rate in our study was 24% 
during the first year post-OLT, which is in keeping with rates 
reported in other studies (28, 29). According to the results 
of both univariate and multivariate analyses, only pre-oper-
ative presence of AFP mRNA was an independent risk factor 
for HCC recurrence. This test would help to identify patients 
who may benefit from more intensive post-LT surveillance, 
altered  immunosuppressive  regimen  or  adjuvant  chemo-
therapy. GPC3 expression is frequently increased in HCC (30). 
In fact, GPC3 may be reactivated in HCC as frequently as AFP, 
which has been used extensively as a marker of this cancer. 
Moreover, GPC3 is reactivated more often than AFP in small 
dysplastic liver nodules and therefore may be a more reliable 
early diagnostic marker than AFP (31-34). Our results showed 
that  GPC3  mRNA  was  generally  expressed  in  PB  which  is 
coincident with previous studies indicating that GPC3 was 
widely expressed in tissues and plasma (35, 36). However, we 
neither detected any significant difference in GPC3 mRNA 
expression between the HCC and control groups, nor have 
we found any relationship between the GPC3 expression in 
PB cells and the tumor recurrence after OLT which suggested 
that GPC3 mRNA test in PB does not have the same diagnos-
tic value as that of measurement of GPC3 protein level in 
plasma (16, 17, 36). In conclusion, AFP mRNA test should be 
considered in the pre-operative workup to adequately select 
suitable patients and the most relevant therapeutic option; 
evaluation of AFP mRNA may provide important clues for 
selecting those patients who need adjuvant chemotherapy 
and intensive follow-up after OLT. But, we should admit that 
AFP mRNA is only recommended as complementary tests to 
the conventionally diagnostic methods used. Future studies 
with higher numbers of patients and longer follow-up need 
to confirm the clinical usefulness of this assay. 
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